Matching-Adjusted Indirect Comparison of Olutasidenib and Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Relapsed/Refractory Acute Myeloid Leukemia.

Watts JM, Wang ES, Jonas BA, Wilson FR, Park JE, Cope S, Sheppard A, Thomassen A, de Botton S, Cortes JE

Open source

DOI
10.1007/s12325-026-03522-6
Published
2026 Apr
Container
Advances in therapy
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s12325-026-03522-6,
  title = {Matching-Adjusted Indirect Comparison of Olutasidenib and Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Relapsed/Refractory Acute Myeloid Leukemia.},
  author = {Watts JM and Wang ES and Jonas BA and Wilson FR and Park JE and Cope S and Sheppard A and Thomassen A and de Botton S and Cortes JE},
  year = {2026},
  journal = {Advances in therapy},
  doi = {10.1007/s12325-026-03522-6},
  url = {https://doi.org/10.1007/s12325-026-03522-6}
}

RIS

TY  - JOUR
TI  - Matching-Adjusted Indirect Comparison of Olutasidenib and Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Relapsed/Refractory Acute Myeloid Leukemia.
AU  - Watts JM
AU  - Wang ES
AU  - Jonas BA
AU  - Wilson FR
AU  - Park JE
AU  - Cope S
AU  - Sheppard A
AU  - Thomassen A
AU  - de Botton S
AU  - Cortes JE
PY  - 2026
JO  - Advances in therapy
DO  - 10.1007/s12325-026-03522-6
UR  - https://doi.org/10.1007/s12325-026-03522-6
ER  - 

APA

JM, W., ES, W., BA, J., FR, W., JE, P., S, C., A, S., A, T., S, D. B., & JE, C. (2026). Matching-Adjusted Indirect Comparison of Olutasidenib and Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Relapsed/Refractory Acute Myeloid Leukemia.. Advances in therapy. https://doi.org/10.1007/s12325-026-03522-6

Source records